Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with or without radiation therapy in treating patients who have esophageal cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
OBJECTIVES:
-
Determine the median and two-year disease-free and overall survival of patients with resectable esophageal cancer treated with neoadjuvant paclitaxel, cisplatin, and fluorouracil with concurrent radiotherapy.
-
Determine the complete and partial responses in patients treated with this regimen.
-
Assess the toxicity of this regimen in these patients.
-
Determine the optimal dose of paclitaxel when administered in this regimen in these patients.
-
Determine the effect of tumor tubulin isoform expression on chemosensitivity and overall survival of patients treated with this regimen.
OUTLINE: Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for 2 courses.
Beginning 3 weeks after completion of initial chemotherapy, patients receive concurrent chemoradiotherapy comprising paclitaxel IV over 1 hour and cisplatin IV over 1 hour on days 1, 8, 15, 22, and 29; fluorouracil IV continuously for 5 weeks; and radiotherapy daily 5 days a week for 5 weeks.
At 4-8 weeks after completion of chemoradiotherapy, patients may undergo surgical resection. Patients with local progressive disease after 2 courses of initial chemotherapy undergo surgical resection instead of receiving concurrent chemoradiotherapy.
Patients are followed within 6 weeks, every 3 months for 3 years, and then annually for 2 years.
PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed adenocarcinoma, squamous cell, adenosquamous, or undifferentiated carcinoma of the esophagus or gastroesophageal junction
-
Potentially resectable disease
-
No malignant celiac node involvement
-
No cervical esophageal carcinoma
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
-
Absolute neutrophil count at least 1,800/mm^3
-
Platelet count at least 100,000/mm^3
Hepatic:
-
Bilirubin no greater than 1.5 times upper limit of normal (ULN)
-
AST no greater than 3 times ULN
Renal:
-
Creatinine no greater than 1.5 mg/dL OR
-
Creatinine clearance at least 60 mL/min
Other:
-
No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
-
No significant medical or psychiatric illness that would preclude study
-
Not pregnant or nursing
-
Fertile patients must use effective contraception during and for at least 3 months after study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy for esophageal cancer
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior thoracic radiotherapy
Surgery:
-
See Disease Characteristics
-
No prior surgical resection of esophageal tumor
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Fox Chase Cancer Center | Philadelphia | Pennsylvania | United States | 19111-2497 |
Sponsors and Collaborators
- Fox Chase Cancer Center
- National Cancer Institute (NCI)
Investigators
- Study Chair: Jonathan Cheng, MD, Fox Chase Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000068769
- P30CA006927
- FCCC-00003
- NCI-G01-1982